Comparative Pharmacology
Head-to-head clinical analysis: ZOMIG versus ZOMIG ZMT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ZOMIG versus ZOMIG ZMT.
ZOMIG vs ZOMIG-ZMT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective 5-HT1B/1D receptor agonist; constricts cranial blood vessels and inhibits trigeminal nerve transmission.
Selective serotonin 5-HT1B/1D receptor agonist; causes vasoconstriction of cranial blood vessels, inhibits trigeminal nerve transmission, and reduces neurogenic inflammation.
2.5 mg orally at onset of migraine; may repeat after 2 hours if needed, maximum 10 mg in 24 hours. Also available as 5 mg nasal spray and 3 mg subcutaneous injection.
2.5 mg orally at onset of migraine; may repeat after 2 hours if needed. Maximum 10 mg in 24 hours.
None Documented
None Documented
Mean terminal elimination half-life is approximately 3 hours (range 2.5-4 hours). In patients with hepatic impairment, half-life may be prolonged (up to 7 hours).
Terminal elimination half-life is approximately 3 to 3.5 hours for zolmitriptan and its active metabolite N-desmethyl zolmitriptan has a similar half-life. This supports a typical dosing interval of at least 2 hours between doses.
Primarily hepatic metabolism via CYP1A2; approximately 10-15% excreted unchanged in urine, with the remainder eliminated as metabolites (mostly N-desmethylzolmitriptan and indoleacetic acid) in urine (60%) and feces (30%).
Approximately 60-70% of the administered dose is excreted in urine, primarily as metabolites (active N-desmethyl zolmitriptan and inactive indoleacetic acid derivatives), with about 10-15% as unchanged drug. Fecal excretion accounts for about 20-30% of the dose.
Category C
Category C
Triptan Antimigraine
Triptan Antimigraine